RAINBO: Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features, TransPORTEC Platform Trials - MMRd-GREEN.
This study is testing a new combination treatment for a specific type of uterine cancer to see if it works better than standard care. Researchers want to find out if adding an immunotherapy medicine, which helps your own immune system fight cancer, to radiation can prevent the cancer from returning after surgery.
You might be able to join if you are 18 or older, have had surgery to remove uterine cancer with no remaining cancer visible, and have specific genetic test results from your tumor tissue. Participants must also be free of other recent cancers and have no history of prior pelvic radiation.
Depending on which group you are placed in, you will receive standard radiation therapy, possibly chemotherapy, or radiation combined with the study immunotherapy medicine called durvalumab for one year. Your health and any side effects will be closely monitored by the medical team through regular check-ups and scans.
This is an international study currently looking for participants and is open at medical centers in locations such as Antwerp, Brussels, and Charleroi in Belgium.
- 1Testing a new immunotherapy medicine combined with radiation for uterine cancer
- 2Compares standard treatments against new combinations based on your tumor's specific genetic features
- 3Currently recruiting participants at multiple hospital locations in Belgium
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.